v3.25.4
Business Combinations - Summary of Preliminary Estimated Fair Values of Assets Acquired and Liabilities Assumed (Detail) - USD ($)
$ in Thousands
Dec. 31, 2025
Nov. 12, 2025
Dec. 31, 2024
Dec. 19, 2024
Dec. 31, 2023
Assets Acquired          
Goodwill $ 43,363   $ 40,330   $ 35,696
BioMedomics, Inc          
Assets Acquired          
Other current and non current assets   $ 10      
Inventory   284      
Operating right-of-use assets   120      
In-process research and development technology intangible asset   1,900      
Goodwill   1,775      
Total assets acquired   4,089      
Liabilities Assumed          
Accounts payable   34      
Current liabilities   17      
Deferred revenue   72      
Operating lease liability   120      
Total liabilities assumed   243      
Net Assets Acquired   3,846      
Estimated fair value of contingent consideration   (233)      
Net Cash Paid   3,613      
Cash acquired in excess of payments to acquire business   $ 25      
Sherlock Biosciences          
Assets Acquired          
Other current assets       $ 2,570  
Property, plant, and equipment, net       9,244  
Other noncurrent assets       462  
Operating right-of-use assets       4,080  
In-process research and development technology intangible asset       17,000  
Goodwill       6,382  
Total assets acquired       39,738  
Liabilities Assumed          
Accounts payable       2,449  
Current liabilities       3,621  
Deferred revenue       1,641  
Operating lease liability       4,080  
Total liabilities assumed       11,791  
Net Assets Acquired       27,947  
Estimated fair value of contingent consideration       (22,910)  
Net Cash Paid       5,037  
Cash acquired in excess of payments to acquire business       $ 402